# An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

> **NCT05741528** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SEP-363856

## Key facts

- **NCT ID:** NCT05741528
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-31
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741528, "An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05741528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*